Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)
Inhibikase Therapeutics' (IKT) quarterly FCF Margin came in at 344243100.0% in Q4 2023, down 34423750523.0% year-on-year from N/an in Q4 2022, and down 6672362.53% on a QoQ basis from 5159.16% in Q3 2023.
Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023) Analysis & Trends
Inhibikase Therapeutics (IKT) has 4 years of FCF Margin data on file, last reported at 344243100.0% in Q4 2023.
- On a quarterly basis, FCF Margin fell 34423750523.0% year-over-year to 344243100.0% in Q4 2023; TTM through Sep 2024 was 1724492300.0%, a 172448668417.0% decrease from a year earlier, with the FY2023 full-year figure at 6947.87%, up 730549.0% from the prior year.
- FCF Margin for Q4 2023 stood at 344243100.0%, down from 5159.16% in the prior quarter.
- Over the last five years, FCF Margin for IKT reached as high as 200.41% in Q3 2020 and fell as low as 344243100.0% in Q4 2023.
- Historically, FCF Margin has averaged 21539540.75% across 4 years, with a median of 4540.49% in 2023.
- Across the five-year window, FCF Margin surged 20509540 bps in 2022 and slumped 2000000000 bps in 2023, its largest moves.
- Year by year, FCF Margin stood at 555.42% in 2020, then slumped by 37833 bps to 210690.17% in 2021, then soared by 97 bps to 5594.77% in 2022, then sank by 6152840 bps to 344243100.0% in 2023.
- Per Business Quant data, the three most recent FCF Margin figures were 344243100.0% in Q4 2023, 5159.16% in Q3 2023, and 3921.82% in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Inhibikase Therapeutics | 55.25 Mn | -115.12 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -344,243,100.00% |
| Sep 30, 2023 | -5,159.16% |
| Jun 30, 2023 | -3,921.82% |
| Mar 31, 2023 | -9,256.10% |
| Dec 31, 2022 | -5,594.77% |
| Sep 30, 2022 | -78,245.73% |
| Jun 30, 2022 | -66,480.49% |
| Mar 31, 2022 | -8,546.84% |
| Dec 31, 2021 | -210,690.17% |
| Sep 30, 2021 | -615.14% |
| Jun 30, 2021 | -311.55% |
| Mar 31, 2021 | -279.58% |
| Dec 31, 2020 | -555.42% |
| Sep 30, 2020 | 200.41% |
| Jun 30, 2020 | -1.33% |
| Mar 31, 2020 | -94.33% |